JTE-013

CAS No. 383150-41-2

JTE-013( —— )

Catalog No. M22938 CAS No. 383150-41-2

JTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively).JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM;?1-3 days) decreased cell viability.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 63 In Stock
10MG 91 In Stock
25MG 202 In Stock
50MG 302 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    JTE-013
  • Note
    Research use only, not for human use.
  • Brief Description
    JTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively).JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM;?1-3 days) decreased cell viability.
  • Description
    JTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively).JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM;?1-3 days) decreased cell viability.?JTE-013 shows 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM.?JTE-013 (10-1000 nM;?30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation.JTE-013 (gavage;?30 mg/kg daily for 14 consecutive days) decreases tumor size and tumor weight.?the modification of JTE-013 to produce the AB1 compound improved potency, intravenous pharmacokinetics, cellular activity, and antitumor activity in NB and may have enhanced clinical and experimental applicability.
  • In Vitro
    JTE-013 (50-200 μM; 1-3 days) reduces cell viability. JTE-013 (10-1000 nM; 30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation.JTE-013 displays 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM. Cell Viability AssayCell Line:SK-N-AS cells Concentration:50, 100, 150, 200 μ Incubation Time:1-3 days Result:Reduced cell viability.Western Blot Analysis Cell Line:SK-N-AS cells Concentration:10, 100, 1000 nM Incubation Time:30 mins Result:Reversed S1P-induced Akt inhibition and inhibited S1P-induced ERK activation.
  • In Vivo
    JTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight. Animal Model:Six-week-old female athymic NCr-nu/nu nude mice Dosage:30 mg/kg Administration:Gavage; daily for 14 consecutive days Result:Reduced tumor size and tumor weight.
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    S1P Receptor
  • Recptor
    S1P2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    383150-41-2
  • Formula Weight
    408.29
  • Molecular Formula
    C17H19Cl2N7O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mg/mL (244.92 mM; Need ultrasonic)
  • SMILES
    CC(C1=C2C(N(C)N=C2C)=NC(NNC(NC3=CC(Cl)=NC(Cl)=C3)=O)=C1)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Li MH, et al. Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma. J Pharmacol Exp Ther. 2015 Sep;354(3):261-8.
molnova catalog
related products
  • GSK2018682

    GSK2018682 is an agonist of sphingosine-1-phosphate receptor ?(s1p1) and (s1p5) agonist(pEC50s of 7.7 and 7.2respectively).

  • W140 HBr

    [(3S)-3-amino-4-(3-hexylanilino)-4-oxobutyl]phosphonic acid;hydrobromide is a S1P1 antagonist with Ki of 2.84 μM.

  • 4-Deoxypyridoxine hy...

    4-Deoxypyridoxine (hydrochloride) inhibits the degradation of intracellular S1P by inhibiting S1P lyase (SPL) activity, minimized the chemically induced apoptosis of insulinoma cell lines as S1P did.